---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-073484"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:14:12.806363+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024

## Summary
- Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.
- Base salary $450k/year; option for 60k shares and 30k restricted stock grant.
- Eligible for annual cash bonus up to 35% of base salary and $10k signing bonus.
- Previously founded BioCentriq, a CDMO acquired for $73M by GC Holdings.
- Appointment supports operational readiness for NurOwn® Phase 3b ALS study.

## SEC filing metadata
- accession: 0001104659-24-073484
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/tm2417625d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-073484
- JSON: https://secwatch.observer/filing/0001104659-24-073484.json
- Plain text: https://secwatch.observer/filing/0001104659-24-073484.txt

## Source-grounded claims
- claim_id: a9c465f3ab
  claim: Hartoun Hartounian was appointed as Executive Vice President and Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..
  evidence_excerpt: On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.